1.Rao, GH, Thethi, I & Fareed, J (2011) Vascular disease: obesity and excess weight as modulators of risk. Expert Rev Cardiovasc Ther 9, 525–534.
2.Kahn, SE, Hull, RL & Utzschneider, KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840–846.
3.Kotsis, V, Stabouli, S, Papakatsika, S, et al. (2010) Mechanisms of obesity-induced hypertension. Hypertens Res 33, 386–393.
4.Wajchenberg, BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21, 697–738.
5.Perrini, S, Leonardini, A, Laviola, L, et al. (2008) Biological specificity of visceral adipose tissue and therapeutic intervention. Arch Physiol Biochem 114, 277–286.
6.Kershaw, EE & Flier, JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89, 2548–2556.
7.Galic, S, Oakhill, JS & Steinberg, GR (2010) Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316, 129–139.
8.Despres, JP & Lemieux, I (2006) Abdominal obesity and metabolic syndrome. Nature 444, 881–887.
9.Nedungadi, TP & Clegg, DJ (2009) Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. J Cardiovasc Transl Res 2, 321–327.
10.Kishida, K, Funahashi, T & Shimomura, I (2011) Clinical significance of visceral fat reduction through health education in preventing atherosclerotic cardiovascular disease – lesson from the Amagasaki Visceral Fat Study: a Japanese perspective. Nutr Metab (Lond) 8, 57.
11.Stefan, N, Kantartzis, K & Haring, HU (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29, 939–960.
12.Mochizuki, K, Miyauchi, R, Misaki, Y, et al. (2011) Accumulation of visceral fat is positively associated with serum ALT and gamma-GTP activities in healthy and preclinical middle-aged Japanese men. J Nutr Sci Vitaminol (Tokyo) 57, 65–73.
13.Bo, S, Gambino, R, Durazzo, M, et al. (2005) Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population based cohort: a possible implication for oxidative stress. World J Gastroenterol 11, 7109–7117.
14.Vozarova, B, Stefan, N, Lindsay, RS, et al. (2002) High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51, 1889–1895.
15.Marchesini, G, Brizi, M, Bianchi, G, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 1844–1850.
16.van Barneveld, T, Seidell, JC, Traag, N, et al. (1989) Fat distribution and gamma-glutamyl transferase in relation to serum lipids and blood pressure in 38-year old Dutch males. Eur J Clin Nutr 43, 809–818.
17.Yanai, H, Tomono, Y, Ito, K, et al. (2007) Diacylglycerol oil for the metabolic syndrome. Nutr J 6, 43.
18.Taguchi, H, Watanabe, H, Onizawa, K, et al. (2000) Double-blind controlled study on the effects of dietary diacylglycerol on postprandial serum and chylomicron triacylglycerol responses in healthy humans. J Am Coll Nutr 19, 789–796.
19.Tada, N, Watanabe, H, Matsuo, N, et al. (2001) Dynamics of postprandial remnant-like lipoprotein particles in serum after loading of diacylglycerols. Clin Chim Acta 311, 109–117.
20.Kamphuis, MM, Mela, DJ & Westerterp-Plantenga, MS (2003) Diacylglycerols affect substrate oxidation and appetite in humans. Am J Clin Nutr 77, 1133–1139.
21.Nagao, T, Watanabe, H, Goto, N, et al. (2000) Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men in a double-blind controlled trial. J Nutr 130, 792–797.
22.Maki, KC, Davidson, MH, Tsushima, R, et al. (2002) Consumption of diacylglycerol oil as part of a reduced-energy diet enhances loss of body weight and fat in comparison with consumption of a triacylglycerol control oil. Am J Clin Nutr 76, 1230–1236.
23.Xie, N, Zhang, W, Li, J, et al. (2011) α-Linolenic acid intake attenuates myocardial ischemia/reperfusion injury through anti-inflammatory and anti-oxidative stress effects in diabetic but not normal rats. Arch Med Res 42, 171–181.
24.Rodriguez-Leyva, D, Dupasquier, CM, McCullough, R, et al. (2010) The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Can J Cardiol 26, 489–496.
25.Dewell, A, Marvasti, FF, Harris, WS, et al. (2011) Low- and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome. J Nutr 141, 2166–2171.
26.de Goede, J, Verschuren, WM, Boer, JM, et al. (2011) Alpha-linolenic acid intake and 10 year incidence of coronary heart disease and stroke in 20,000 middle-aged men and women in the Netherlands. PLoS One 6, e17967.
27.Kaul, N, Kreml, R, Austria, JA, et al. (2008) A comparison of fish oil, flaxseed oil and hempseed oil supplementation on selected parameters of cardiovascular health in healthy volunteers. J Am Coll Nutr 27, 51–58.
28.Barcelo-Coblijn, G, Murphy, EJ, Othman, R, et al. (2008) Flaxseed oil and fish-oil capsule consumption alters human red blood cell n-3 fatty acid composition: a multiple-dosing trial comparing 2 sources of n-3 fatty acid. Am J Clin Nutr 88, 801–809.
29.Svilaas, A, Strom, EC, Svilaas, T, et al. (2002) Reproducibility and validity of a short food questionnaire for the assessment of dietary habits. Nutr Metab Cardiovasc Dis 12, 60–70.
30.Bastani, NE, Gundersen, TE & Blomhoff, R (2009) Determination of 8-epi PGF(2alpha) concentrations as a biomarker of oxidative stress using triple-stage liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 23, 2885–2890.
31.Panfili, G, Fratianni, A & Irano, M (2003) Normal phase high-performance liquid chromatography method for the determination of tocopherols and tocotrienols in cereals. J Agric Food Chem 51, 3940–3944.
32.Haug, IJ, Sagmo, LB, Zeiss, D, et al. (2011) Bioavailability of EPA and DHA delivered by gelled emulsions and soft gel capsules. Eur J Lipid Sci Technol 113, 137–145.
33.Stefan, N, Hennige, AM, Staiger, H, et al. (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29, 853–857.
34.Arterburn, LM, Hall, EB & Oken, H (2006) Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 83, 1467S–1476S.
35.Ridker, PM, Buring, JE, Rifai, N, et al. (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297, 611–619.
36.Ridker, PM, Paynter, NP, Rifai, N, et al. (2008) C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118, 2243–2251.
37.Yanagisawa, Y, Kawabata, T, Tanaka, O, et al. (2003) Improvement in blood lipid levels by dietary sn-1,3-diacylglycerol in young women with variants of lipid transporters 54T-FABP2 and -493g-MTP. Biochem Biophys Res Commun 302, 743–750.
38.Teramoto, T, Watanabe, H, Ito, K, et al. (2004) Significant effects of diacylglycerol on body fat and lipid metabolism in patients on hemodialysis. Clin Nutr 23, 1122–1126.
39.Taguchi, H, Nagao, T, Watanabe, H, et al. (2001) Energy value and digestibility of dietary oil containing mainly 1,3-diacylglycerol are similar to those of triacylglycerol. Lipids 36, 379–382.
40.Hara, K, Onizawa, K, Honda, H, et al. (1993) Dietary diacylglycerol-dependent reduction in serum triacylglycerol concentration in rats. Ann Nutr Metab 37, 185–191.
41.Tada, N (2004) Physiological actions of diacylglycerol outcome. Curr Opin Clin Nutr Metab Care 7, 145–149.
42.Rudkowska, I, Roynette, CE, Demonty, I, et al. (2005) Diacylglycerol: efficacy and mechanism of action of an anti-obesity agent. Obes Res 13, 1864–1876.
43.Murata, M, Ide, T & Hara, K (1997) Reciprocal responses to dietary diacylglycerol of hepatic enzymes of fatty acid synthesis and oxidation in the rat. Br J Nutr 77, 107–121.
44.Murase, T, Aoki, M, Wakisaka, T, et al. (2002) Anti-obesity effect of dietary diacylglycerol in C57BL/6J mice: dietary diacylglycerol stimulates intestinal lipid metabolism. J Lipid Res 43, 1312–1319.
45.Murase, T, Nagasawa, A, Suzuki, J, et al. (2002) Dietary alpha-linolenic acid-rich diacylglycerols reduce body weight gain accompanying the stimulation of intestinal beta oxidation and related gene expressions in C57BL/KsJ-db/db mice. J Nutr 132, 3018–3022.
46.Meng, X, Zou, D, Shi, Z, et al. (2004) Dietary diacylglycerol prevents high-fat diet-induced lipid accumulation in rat liver and abdominal adipose tissue. Lipids 39, 37–41.
47.Murase, T, Aoki, M & Tokimitsu, I (2005) Supplementation with alpha-linolenic acid-rich diacylglycerol suppresses fatty liver formation accompanied by an up-regulation of beta oxidation in Zucker fatty rats. Biochim Biophys Acta 1733, 224–231.
48.Hibi, M, Takase, H, Yasunaga, K, et al. (2008) Greater fat oxidation with diacylglycerol oil consumption for 14 days compared with triacylglycerol oil consumption in overweight men and women. Int J Obes (Lond) 32, 1841–1847.
49.Saito, S, Tomonobu, K, Hase, T, et al. (2006) Effects of diacylglycerol on postprandial energy expenditure and respiratory quotient in healthy subjects. Nutrition 22, 30–35.
50.Hibi, M, Takase, H, Yasunaga, K, et al. (2008) Fat utilization in healthy subjects consuming diacylglycerol oil diet: dietary and whole body fat oxidation. Lipids 43, 517–524.
51.Kimura, S, Tsuchiya, H, Inage, H, et al. (2006) Effects of dietary diacylglycerol on the energy metabolism. Int J Vitam Nutr Res 76, 75–79.
52.Jensen, MD, Haymond, MW, Rizza, RA, et al. (1989) Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 83, 1168–1173.
53.Bjorntorp, P, Bergman, H & Varnauskas, E (1969) Plasma free fatty acid turnover rate in obesity. Acta Med Scand 185, 351–356.
54.Boden, G (2011) Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 18, 139–143.
55.Boden, G, Chen, X, Ruiz, J, et al. (1994) Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 93, 2438–2446.
56.Santomauro, AT, Boden, G, Silva, ME, et al. (1999) Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48, 1836–1841.
57.Yamamoto, K, Asakawa, H, Tokunaga, K, et al. (2001) Long-term ingestion of dietary diacylglycerol lowers serum triacylglycerol in type II diabetic patients with hypertriglyceridemia. J Nutr 131, 3204–3207.
58.Yasunaga, K, Glinsmann, WH, Seo, Y, et al. (2004) Safety aspects regarding the consumption of high-dose dietary diacylglycerol oil in men and women in a double-blind controlled trial in comparison with consumption of a triacylglycerol control oil. Food Chem Toxicol 42, 1419–1429.
59.Vohl, MC, Sladek, R, Robitaille, J, et al. (2004) A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res 12, 1217–1222.
60.Havel, PJ (2004) Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53, Suppl. 1, S143–S151.
61.Nelson, TL, Stevens, JR & Hickey, MS (2007) Inflammatory markers are not altered by an eight week dietary alpha-linolenic acid intervention in healthy abdominally obese adult males and females. Cytokine 38, 101–106.
62.Rallidis, LS, Paschos, G, Liakos, GK, et al. (2003) Dietary alpha-linolenic acid decreases C reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. Atherosclerosis 167, 237–242.
63.Zhao, G, Etherton, TD, Martin, KR, et al. (2004) Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr 134, 2991–2997.
64.Bemelmans, WJ, Lefrandt, JD, Feskens, EJ, et al. (2004) Increased alpha-linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis. Eur J Clin Nutr 58, 1083–1089.
65.Kotsis, V, Stabouli, S, Bouldin, M, et al. (2005) Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension 45, 602–607.
66.Stabouli, S, Kotsis, V, Papamichael, C, et al. (2005) Adolescent obesity is associated with high ambulatory blood pressure and increased carotid intimal-medial thickness. J Pediatr 147, 651–656.
67.Stamler, J, Stamler, R & Neaton, JD (1993) Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 153, 598–615.
68.MacMahon, S, Cutler, J, Brittain, E, et al. (1987) Obesity and hypertension: epidemiological and clinical issues. Eur Heart J 8, Suppl. B, 57–70.
69.Meguro, S, Higashi, K, Hase, T, et al. (2001) Solubilization of phytosterols in diacylglycerol versus triacylglycerol improves the serum cholesterol-lowering effect. Eur J Clin Nutr 55, 513–517.
70.Kim, CH, Park, JY, Lee, KU, et al. (2009) Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab Res Rev 25, 64–69.
71.Ford, ES, Schulze, MB, Bergmann, MM, et al. (2008) Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam Study. Diabetes Care 31, 1138–1143.
72.Doi, Y, Kubo, M, Yonemoto, K, et al. (2007) Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring) 15, 1841–1850.
73.Wannamethee, SG, Shaper, AG, Lennon, L, et al. (2005) Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28, 2913–2918.
74.Murase, T, Mizuno, T, Omachi, T, et al. (2001) Dietary diacylglycerol suppresses high fat and high sucrose diet-induced body fat accumulation in C57BL/6J mice. J Lipid Res 42, 372–378.
75.Austria, JA, Richard, MN, Chahine, MN, et al. (2008) Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed. J Am Coll Nutr 27, 214–221.
76.Yamamoto, K, Tomonobu, K, Asakawa, H, et al. (2006) Diet therapy with diacylglycerol oil delays the progression of renal failure in type 2 diabetic patients with nephropathy. Diabetes Care 29, 417–419.
77.Matsuyama, T, Shoji, K, Watanabe, H, et al. (2006) Effects of diacylglycerol oil on adiposity in obese children: initial communication. J Pediatr Endocrinol Metab 19, 795–804.